• Mobilizing the Immune System

    A clinical-stage biopharmaceutical company leveraging from its multiple drug development platforms to treat patients with inflammatory diseases, viral infections, and cancer.
  • ABX464

    Fighting Inflammatory Diseases

    Abivax’s lead candidate ABX464, a potent anti-inflammatory agent, is entering a Phase 2b clinical trial for its potential to bring clinical benefit to patients with ulcerative colitis, and potentially other inflammatory indications.
  • ABX464

    Developing a Functional Cure for HIV

    ABX464 is a Phase 2 candidate designed to functionally cure HIV by reducing the viral reservoir and is the first ever drug candidate to demonstrate this reduction in patients.
  • ABX196

    Tackling Cancer

    A small molecule agonist of invariant Natural Killer T-Cells (iNKT) to be tested in Phase 1/2 clinical trial for treatment of hepatocellular carcinoma (HCC).

About Us

Abivax is developing therapies that stimulate the body’s natural immune system machinery. A clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to develop drug candidates to treat ulcerative colitis, HIV, and liver cancer.

Its lead clinical candidate, ABX464, has demonstrated the potential to address indications in two disease areas: treatment of inflammation in ulcerative colitis and reduction of the viral reservoir in HIV.

Learn More View our Corporate Presentation

 

On November 9, 2018, Abivax hosted a KOL lunch event focused on the mid-stage testing of ABX464 in Ulcerative Colitis and HIV.

View Recorded Webcast

 

Pipeline

With three products in clinical trials and four products in Research and Preclinical development, Abivax’s pipeline is strong and diversified, addressing many unmet needs.

Clinical Programs

  • ABX464 UC

    ABX464 is an oral, first-in-class small molecule that has demonstrated anti-inflammatory activity in preclinical trials and shown impressive clinical safety and efficacy results in a Phase 2a proof of concept study in patients with ulcerative colitis.

    Read More
  • ABX464 HIV

    ABX464 is an oral, first-in-class, novel, small molecule inhibiting HIV replication through an entirely new mechanism of action. For the first time in the treatment of HIV, this molecule could reduce or eliminate the viral reservoirs, and thus potentially deliver a long-lasting virological suppression in HIV-patients.

    Read More
  • ABX464 Crohn’s Disease
  • ABX464 Rheumatoid Arthritis
  • ABX196 HCC

    ABX196 has been developed as a synthetic agonist of iNKT cells from a proprietary platform technology that identifies cells with immune enhancing potential in cancer models.

    Read More

Science

Based on innovative research driven by the idea of stimulating the body’s natural immune system mechanisms to cure diseases.

Read More

News & Events

View More

Investors

Abivax SA has been listed on the Paris stock exchange since June 26, 2015.

View More

Symbol

ABVX